eISSN (Online): 2598-0580



Bioscientia Medicina: Journal of Biomedicine & Translational Research

Journal Homepage: www.bioscmed.com

Intracrine Dynamics of Luminal Breast Cancer: Correlating Intratumoral Estradiol with Estrogen Receptor Alpha Overexpression in an Advanced-Stage Cohort

Erdiansyah Reza Lesmana[1*], Widyanti Soewoto[2], Brian Wasita[3]

[1]Department of Surgery, Faculty of Medicine, Universitas Sebelas Maret/Dr. Moewardi Regional General Hospital, Surakarta, Indonesia

[2]Department of Oncology Surgery, Faculty of Medicine, Universitas Sebelas Maret/Dr. Moewardi Regional General Hospital, Surakarta, Indonesia

[3]Department of Pathological Anatomy, Faculty of Medicine, Universitas Sebelas Maret/Dr. Moewardi Regional General Hospital, Surakarta, Indonesia

ARTICLE INFO

Keywords:
Breast neoplasms
Estrogen receptor alpha
Intracrineology
Luminal subtypes
Immunohistochemistry

***Corresponding author:**
Erdiansyah Reza Lesmana

E-mail address:
erdiansyahreza@gmail.com

All authors have reviewed and approved the final version of the manuscript.

https://doi.org/10.37275/bsm.v10i3.1542

A B S T R A C T

Background: In postmenopausal breast cancer, systemic serum estradiol levels often fail to reflect the biologically active concentrations within the tumor microenvironment, a phenomenon known as intracrineology. While the roles of estrogen receptor alpha (ERα) and beta (ERβ) are well-characterized, the specific relationship between local ligand concentration and receptor expression in advanced-stage malignancies remains under-investigated. This study investigates the correlation between intratumoral estradiol (E2) concentration and the expression of ER isoforms in Luminal A and Luminal B subtypes. **Methods:** A retrospective cross-sectional study was conducted on 56 tissue samples (38 Luminal A, 18 Luminal B) from patients at Dr. Moewardi Regional General Hospital, Indonesia. Pre-analytical variables were strictly controlled, ensuring cold ischemia time was less than one hour. Expressions of E2, ERα, and ERβ were quantified using immunohistochemistry and assessed via H-Scores. Due to non-normal data distribution, associations were analyzed using Spearman's Rho and Generalized Linear Models (GLM) with a Gamma distribution and log-link function, coupled with bootstrapping to generate robust confidence intervals. **Results:** The cohort was characterized by advanced disease, with 85.7% of patients presenting with Stage III or IV breast cancer. Luminal A tumors exhibited significantly higher mean intratumoral E2 (91.58 versus 56.67; p = 0.038) and ERα expression (122.23 versus 109.72; p = 0.045) compared to Luminal B. A significant positive correlation was observed between tissue E2 and ERα (Rho = 0.347; p = 0.009). GLM analysis confirmed E2 as a significant predictor of ERα expression (p = 0.015), independent of age and stage. No significant correlation was found between E2 and ERβ (p = 0.113). **Conclusion:** Intratumoral estradiol is a significant positive correlate of ERα expression in luminal breast cancer, supporting the existence of a ligand-driven autocrine maintenance loop even in advanced stages. The lack of correlation with ERβ suggests divergent regulatory mechanisms. These findings reinforce the rationale for therapies targeting local aromatase activity.

1. Introduction

Breast cancer represents a heterogeneous group of neoplastic diseases characterized by distinct molecular profiles and divergent clinical outcomes. Despite advances in early detection and multimodal therapy, it remains the most prevalent malignancy in women globally, with an estimated 2.3 million new diagnoses annually. In Southeast Asia, and

particularly in Indonesia, the disease burden is compounded by delayed presentation, with a significant proportion of patients diagnosed at locally advanced or metastatic stages (Stage III and IV). This distinct demographic profile presents unique biological challenges, as tumor biology in advanced stages may differ significantly from the early-stage disease often profiled in Western literature.[1,2]

The cornerstone of systemic management for the majority of these tumors lies in targeting the estrogen signaling pathway, as approximately 70% to 75% of breast cancers express the estrogen receptor (ER). The biological activity of estrogens is mediated primarily by two distinct nuclear receptors: Estrogen receptor alpha (ERα), encoded by the ESR1 gene, and estrogen receptor beta (ERβ), encoded by the ESR2 gene.[3] ERα is the classic driver of cellular proliferation and survival in breast cancer cells and serves as the primary predictive biomarker for response to endocrine therapies such as Tamoxifen and Aromatase Inhibitors. Conversely, ERβ has been increasingly characterized as a tumor suppressor that antagonizes ERα-mediated transcription, inhibits cell cycle progression, and promotes apoptosis. The balance between these two receptors is crucial for determining the ultimate biological behavior of the tumor.[4,5]

Clinical classification segregates ER-positive tumors into Luminal A and Luminal B subtypes based on proliferation markers, specifically Ki-67, and HER2 status. Luminal A tumors are characterized by high ER expression, low proliferation, and a generally favorable prognosis. Luminal B tumors, conversely, exhibit higher proliferative indices, variable HER2 expression, and a more aggressive clinical course. Despite this well-established classification, the specific hormonal microenvironment driving these phenotypes remains under-investigated.[6,7]

A critical limitation in current oncological practice is the reliance on systemic or serum estradiol levels to gauge hormonal status. In postmenopausal women, who constitute the majority of breast cancer patients, ovarian estrogen production ceases, and serum estradiol levels are often negligible. However, breast tumors possess the enzymatic machinery—specifically aromatase and sulfatase—to synthesize estradiol de novo from circulating androgens or estrone sulfate. This intracrine physiology results in intratumoral estradiol concentrations that can be 10 to 50 times higher than plasma levels, effectively fueling tumor growth despite systemic estrogen depletion.[8]

Current literature lacks sufficient data correlating these local tissue estradiol concentrations directly with the differential expression of ERα and ERβ within specific Luminal subtypes. This is particularly relevant in cohorts dominated by advanced-stage disease, where mechanisms of endocrine resistance may already be active. Furthermore, statistical methodologies in prior studies have often relied on parametric assumptions that do not hold for biological expression data, potentially obscuring complex non-linear relationships. Understanding whether high local ligand availability correlates with receptor upregulation (positive feedback) or downregulation (negative feedback) is vital for refining therapeutic strategies.[9,10]

This study aims to determine the correlation between intratumoral estradiol expression and the expression of ERα and ERβ in Luminal A and Luminal B breast cancer tissues. To our knowledge, this is one of the first studies in the region to utilize quantitative H-Scores and robust generalized linear modeling to map the ligand-receptor interplay specifically within the tumor microenvironment of an advanced-stage cohort. By moving beyond serum markers, we seek to elucidate the estrogenic drive mechanism that differentiates indolent Luminal A from aggressive Luminal B phenotypes.

2. Methods

This investigation utilized a retrospective cross-sectional design. The study was conducted at the Department of Anatomic Pathology, Dr. Moewardi Regional General Hospital, Surakarta, Central Java, a tertiary referral center handling a high volume of complex oncological cases. The study period spanned

from December 2022 to December 2023. Ethical approval was obtained from the Institutional Review Board (IRB) prior to data collection, ensuring strict compliance with the Declaration of Helsinki regarding the use of human tissue for research purposes.

The population comprised patients with a histologically confirmed diagnosis of invasive breast carcinoma of no special type (NST), molecularly subtyped as Luminal A or Luminal B. The study included patients with a primary breast cancer diagnosis who had available formalin-fixed paraffin-embedded (FFPE) tissue blocks with adequate tumor cellularity, defined as greater than 10% tumor content. Complete clinicopathological data, including age, clinical stage, and status of ER, PR, HER2, and Ki-67, were required for inclusion. To ensure the validity of receptor expression analysis, strict exclusion criteria were applied. Patients who received neoadjuvant chemotherapy or hormonal therapy prior to surgery were excluded to avoid alteration of receptor expression profiles. Furthermore, tissue blocks exhibiting extensive necrosis or autolysis were excluded to prevent artifacts in immunohistochemical staining.

Sample size determination was calculated based on a bivariate correlation hypothesis (one-sided), utilizing a Type I error of 0.05 and a Type II error of 0.20 (Power 80%). Based on preliminary data suggesting a correlation coefficient of 0.35, the minimum required sample was 38. To ensure sufficient power for multivariate modeling, we utilized a total sampling technique, resulting in a final cohort of 56 patients (38 Luminal A and 18 Luminal B).

Recognizing the lability of hormone receptors and phosphoproteins, strict pre-analytical quality control was mandated. Surgical specimens were transported immediately from the operating theater to the pathology laboratory. The cold ischemia time (CIT)—defined as the time interval from tumor excision to immersion in fixative—was verified to be less than one hour for all included samples. Prolonged ischemia is known to artificially degrade antigenicity and result in false-negative or reduced intensity staining. Specimens were fixed in 10% neutral buffered formalin for a minimum of 6 hours and a maximum of 72 hours, adhering strictly to the ASCO/CAP 2020 guidelines.

Expression levels of Estradiol (E2), ERα, and ERβ were quantified using Immunohistochemistry on 4-micron tissue sections. The protocol was standardized as follows: (1) Preparation: Slides were coated with poly-L-lysine and incubated overnight at 37°C; (2) Deparaffinization and Rehydration: Serial immersion in xylol and graded alcohols (absolute, 95%, 70%) was performed, followed by washing in Phosphate Buffered Saline (PBS); (3) Antigen Retrieval: This critical step was performed in a microwave using Tris-EDTA buffer (pH 9.0) at 90°C for 20 minutes to unmask epitopes cross-linked by formalin fixation; (4) Blocking: Endogenous peroxidase activity was quenched with 3% methanol/H_2O_2, followed by incubation with a protein block to prevent non-specific binding; (5) Primary Antibody Incubation: Slides were incubated for 18 hours at 4°C with specific monoclonal antibodies obtained from Abbkine, Inc. The clones used were: (i) ERα: Clone 1D5 (Validated against standard SP1 rabbit monoclonal clones); (ii) ERβ: Clone 14C8; (iii) 17β-Estradiol: Polyclonal antibody targeting tissue-bound steroid; (6) Detection: A streptavidin-biotin-peroxidase complex system (DAB substrate) was used for visualization, and nuclei were counterstained with hematoxylin.

To capture the dynamic range of protein expression, the Histochemical Score (H-Score) was employed rather than a binary classification. Two independent pathologists, blinded to the clinical data, evaluated the slides. The H-Score combines staining intensity (0 = negative, 1 = weak, 2 = moderate, 3 = strong) and the percentage of positive cells (0 to 100). The formula used was:

H-Score = Sum of (Intensity × Percentage of cells with that intensity)

The resulting score ranges from 0 to 300. This continuous variable allows for more granular statistical analysis than simple percentage positivity.

Data were analyzed using SPSS version 27.0 (IBM Corp, Armonk, NY) and R Statistical Software. The Kolmogorov-Smirnov test was applied to all continuous variables. The results indicated that E2, ERα, and ERβ H-Scores followed a non-normal distribution ($p < 0.05$). The Mann-Whitney U test was used to compare median H-Scores between Luminal A and Luminal B groups. Spearman's Rho correlation was used to assess the monotonic relationship between E2 and receptors. Standard linear regression relies on assumptions of normality of residuals and homoscedasticity, which are often violated in biological expression data. Therefore, we employed a generalized linear model (GLM). A Gamma distribution with a log-link function was selected to model the positively skewed H-Score data. This approach allows for robust estimation of the relationship between predictors (estradiol, age, stage) and the outcome (ERα) without transforming the raw data. To further ensure the robustness of the estimates given the sample size of 56, we performed bootstrapping with 1,000 resamples to generate Bias-Corrected and Accelerated (BCa) 95% Confidence Intervals (CIs). Significance was set at $p < 0.05$.

3. Results

Table 1 outlines the demographic and clinicopathological profile of the 56 female patients included in the final analysis. The study population was predominantly postmenopausal, with 60.7% of patients aged over 50 years, aligning with the established epidemiology of luminal-type breast carcinoma which typically affects older women. A distinguishing characteristic of this cohort was the high frequency of advanced disease presentation. Specifically, 85.7% of the patients were diagnosed with Stage III (46.4%) or Stage IV (39.3%) malignancies, while only a minority (14.3%) presented with early-stage disease (Stage I or IIA). This distribution highlights a cohort with significant tumor burden, likely attributable to delayed diagnosis common in the region's tertiary referral settings. In terms of molecular subtyping, the majority of tumors were classified as Luminal A (67.9%), which are traditionally associated with indolent growth, though the advanced staging in this group suggests a complex clinical picture. Luminal B subtypes comprised the remaining 32.1%, split between HER2-negative (17.8%) and HER2-positive (14.3%) variants. Furthermore, baseline immunohistochemistry revealed that 47.5% of the tumors exhibited high H-Scores for intratumoral estradiol, suggesting active local steroidogenesis, while 14.3% were classified as high positive for ERα. These demographic and clinical data establish that the study investigates a population of postmenopausal women with advanced, hormone-dependent breast cancer, providing a critical context for analyzing the intracrine regulation of tumor progression.

Table 2 delineates the differential expression profiles of intratumoral estradiol and estrogen receptor isoforms across the studied molecular subtypes. A key finding is the significant heterogeneity in local ligand availability; Luminal A tumors demonstrated a markedly higher mean H-Score for intratumoral estradiol compared to the more aggressive Luminal B subtype (91.58 vs. 56.67; $p = 0.038$). This elevated local estrogenicity in Luminal A was concomitant with significantly higher expression levels of estrogen receptor alpha (ERα) (122.23 vs. 109.72; $p = 0.045$).

This parallel upregulation reinforces the biological plausibility of a positive feed-forward loop, where high local ligand concentrations stabilize the proliferative receptor, a dynamic that appears less robust in the Luminal B phenotype. Conversely, the analysis revealed no significant inter-group variance in Estrogen Receptor Beta (ERβ) expression ($p = 0.892$), with both subtypes exhibiting comparable mean H-Scores (81.84 vs. 80.83). This lack of discrimination suggests that while the E2-ERα axis is a critical differentiator of luminal biology, ERβ expression is likely governed by alternative, non-ligand-dependent regulatory mechanisms that are conserved across both subtypes in this advanced-stage cohort.

Table 1. Demographic and Clinical Characteristics of the Study Cohort (n=56)

CHARACTERISTIC	CATEGORY	FREQUENCY (N)	PERCENTAGE (%)
Age Group	< 50 Years (Pre-menopausal)	22	39.3%
	> 50 Years (Post-menopausal)	34	60.7%
Clinical Stage	Early (I - IIA)	5	8.9%
	Intermediate (IIB)	3	5.4%
	Advanced (III)	26	46.4%
	Late/Metastatic (IV)	22	39.3%
Molecular Subtype	Luminal A	38	67.9%
	Luminal B (HER2 Negative)	10	17.8%
	Luminal B (HER2 Positive)	8	14.3%
IHC Profile (Categorical)	ERα High Positive	8	14.3%
	Estradiol High Positive	21	47.5%

Table 2. Comparative H-Score Analysis of Estradiol and ER Isoforms

VARIABLE	GROUP	N	MEAN H-SCORE	SD	RANGE (MIN-MAX)	P-VALUE (Mann-Whitney)
Tissue Estradiol (E2)	Luminal A	38	91.58	60.20	0 - 180	**0.038***
	Luminal B	18	56.67	56.67	10 - 160	
ER Alpha (ERα)	Luminal A	38	122.23	74.51	10 - 300	**0.045***
	Luminal B	18	109.72	77.01	10 - 285	
ER Beta (ERβ)	Luminal A	38	81.84	66.89	0 - 220	*0.892*
	Luminal B	18	80.83	82.43	0 - 285	

** Significant at $p < 0.05$*

Data presented as Mean ± Standard Deviation

Figure 1 graphically delineates the bivariate distribution and monotonic association between intratumoral 17β-estradiol (E2) concentrations and estrogen receptor alpha (ERα) expression across the study cohort (n=56). The scatter plot reveals a statistically significant, moderate positive correlation ($\rho = 0.347$; $p = 0.009$), visually represented by the ascending linear regression trendline which indicates that increments in local ligand concentration are

generally accompanied by proportional increases in receptor density. Observing the subtype stratification, distinct clustering patterns emerge that corroborate the tabular data. The Luminal A cohort (represented by teal markers) predominantly occupies the upper-right quadrant, characterizing a phenotype defined by high local ligand availability concomitant with robust receptor overexpression. This distribution visually reinforces the quantitative finding of significantly elevated mean H-Scores in this subgroup. Conversely, the Luminal B cohort (red markers) exhibits a more dispersed distribution situated towards the lower-left and central regions of the plot, indicating reduced intracrine activity and greater heterogeneity in receptor status. The positive slope of the trendline provides empirical support for the hypothesized feed-forward autocrine mechanism, wherein elevated intratumoral estradiol levels stabilize ERα protein turnover, thereby maintaining high receptor density. Notably, the heteroscedastic spread of data points around the trendline—particularly in the mid-range values—suggests that while estradiol is a significant predictor, other biological variables likely influence receptor expression. This visual analysis confirms that the E2-ERα axis remains a coherent and active pathway even within this advanced-stage population, contrasting with the lack of correlation observed in the ERβ analysis, and underscores the biological interdependence of the ligand and its proliferative receptor.



Figure 1. Scatter plot analysis of ligand-receptor dynamics.

Table 3 presents the results of the multivariate generalized linear model (GLM) analysis, constructed to rigorously assess the independent predictive value of intratumoral estradiol on estrogen receptor alpha (ERα) expression while adjusting for potential confounders including patient age and clinical stage.

Given the non-normal, positively skewed distribution of the immunohistochemical H-Score data, a Gamma regression with a log-link function was employed, supplemented by bootstrapping (k=1,000) to generate robust Bias-Corrected and Accelerated (BCa) confidence intervals.

The model confirms that intratumoral estradiol concentration serves as a statistically significant, independent positive predictor of ERα levels (B = 0.004; p = 0.015). The positive coefficient indicates that for every unit increase in the local estradiol H-Score, there is a multiplicative increase in the expected ERα expression, substantiating the bivariate correlation observed in the preliminary analysis. Notably, the analysis revealed that neither chronological age (p = 0.502) nor clinical stage (p > 0.05 for both Stage III and IV relative to early-stage references) exerted a significant independent influence on receptor density within this model. This suggests that the intracrine regulation of ERα is a primary biological driver that persists regardless of the patient's age or the anatomical extent of the disease. The model diagnostics, evidenced by a Deviance/df ratio of 1.12, indicate a robust goodness-of-fit, reinforcing the validity of local estradiol as a key determinant of the receptor profile in luminal breast carcinoma.

Table 3. Generalized Linear Model (GLM) Predicting ERα Expression

Model Type: Gamma Distribution with Log Link Function | Bootstrapped (k=1000)

PREDICTOR	COEFFICIENT (B)	STANDARD ERROR (SE)	WALD CHI-SQUARE	P-VALUE	95% CI (BOOTSTRAPPED)
Intercept	4.650	0.210	489.2	< 0.001	[4.23, 5.06]
Intratumoral Estradiol	**0.004**	0.001	5.942	**0.015***	**[0.001, 0.007]**
Age (Years)	0.002	0.003	0.450	0.502	[-0.004, 0.008]
Clinical Stage (Ref: Early I-II)	-	-	-	-	-
Stage III	-0.120	0.150	0.640	0.424	[-0.410, 0.170]
Stage IV	-0.180	0.160	1.260	0.261	[-0.490, 0.130]

* Significant at p < 0.05.
Adjusted for Age and Stage.

Model Fit: AIC = 642.5 | Deviance/df = 1.12

4. Discussion

The results of this study illuminate the intricate and often overlooked intracrine dimension of breast cancer biology, providing robust quantitative evidence that intratumoral estradiol (E2) functions not merely as a passive fuel, but as a specific, dose-dependent driver of estrogen receptor alpha (ERα) expression. This relationship establishes a potent positive correlation that persists even within a cohort dominated by locally advanced and metastatic disease.[11] Our data suggest that the tumor microenvironment in postmenopausal women evolves into an autonomous endocrine organ capable of synthesizing its own ligand to maintain the high receptor density required for continued proliferation. This finding is particularly salient given the advanced clinical stage of our population, challenging the conventional paradigm that aggressive, bulky tumors invariably lose their hormonal dependence.[12] By demonstrating that local estradiol levels correlate significantly with ERα but show no regulatory impact on estrogen receptor beta (ERβ), we delineate a

divergence in receptor regulation that has profound implications for understanding tumor evolution and refining therapeutic strategies in high-burden disease.



Figure 2. Estradiol-ERα feed-forward loop.

Our primary finding of a significant positive correlation (Spearman's Rho = 0.347; p = 0.009) between intratumoral estradiol and ERα supports the existence of a robust feed-forward autocrine loop. In classical endocrine physiology, hormonal systems often rely on negative feedback loops to maintain homeostasis. However, in the context of neoplastic transformation, this regulatory logic appears to be inverted. Our data indicate that high local concentrations of estradiol do not downregulate the receptor; on the contrary, they appear to be essential for maintaining its overexpression. Biologically, this phenomenon can be explained by the structural dynamics of the nuclear receptor itself. The estrogen receptor alpha is an unstable protein with a short half-life in its unliganded state. In the absence of estradiol, the receptor is prone to misfolding and is rapidly targeted for ubiquitination and subsequent degradation by the 26S proteasome.[13] However, the binding of estradiol induces a profound conformational change in the receptor's ligand-binding domain (LBD). Specifically, ligand binding

positions Helix 12 of the receptor to seal the ligand-binding pocket, creating a compact, stable structure. This agonist-induced stabilization protects the receptor from proteolytic enzymes and prevents rapid turnover. Furthermore, this stable conformation facilitates the recruitment of co-activator proteins, such as SRC-1 and AIB1, which not only enhance transcriptional activity but also further stabilize the receptor complex.[14]

Therefore, the positive correlation observed in our study likely reflects this molecular survivorship: tumors with high local aromatase activity produce sufficient estradiol to saturate and stabilize their ERα population, leading to the high H-Scores observed in immunohistochemistry. Conversely, tumors with lower local estrogen synthesis may suffer from higher rates of receptor degradation, resulting in lower ERα expression. This mechanism creates a self-sustaining cycle of proliferation, where the tumor synthesizes the fuel (via aromatase) and simultaneously preserves the engine (ERα) required to utilize it.[15]

This feed-forward dynamic was notably stronger and more consistent in the Luminal A subtype. Our Luminal A cohort exhibited significantly higher mean levels of both intratumoral E2 (Mean H-Score: 91.58) and ERα (Mean H-Score: 122.23) compared to Luminal B. Pathophysiologically, this aligns with the characterization of Luminal A tumors as the most hormone-addicted phenotype. These tumors appear to have maximized their evolutionary fitness by optimizing this intracrine loop, allowing them to thrive even in the low-estrogen systemic environment of postmenopause.[16] The strong correlation suggests that in Luminal A tumors, the proliferation is driven almost exclusively by this estrogenic axis, making them exquisitely sensitive to endocrine manipulation. This validates the superior clinical efficacy of Aromatase Inhibitors (AIs) over Tamoxifen in this specific subgroup. While Tamoxifen blocks the receptor, it does not stop the ligand-induced stabilization or the non-genomic signaling effects of estradiol. Aromatase Inhibitors, by physically dismantling the local fuel supply, disrupt this stabilization loop, leading to the degradation of the receptor and the collapse of the proliferative drive.

A critical and differentiating finding of this study is the complete lack of significant correlation between intratumoral estradiol and Estrogen Receptor Beta (ERβ) expression ($p = 0.113$). While ERα levels tracked closely with local ligand availability, ERβ expression appeared stochastic and independent of the hormonal microenvironment. This decoupling highlights the distinct biological identity of the beta isoform and suggests that its regulation is governed by fundamentally different mechanisms. Unlike ERα, which functions as the primary activator of proliferation, ERβ acts as a check on cellular growth, often described as a trans-dominant repressor. When co-expressed with ERα, ERβ can form heterodimers (ERα/ERβ) that bind to DNA but fail to recruit the necessary co-activators for transcription, effectively acting as a molecular brake on the ERα drive. The absence of a correlation with estradiol suggests that ERβ protein stability is not ligand-dependent in the same manner as ERα. Instead, current literature suggests that ERβ regulation is primarily epigenetic. The ESR2 gene promoter is rich in CpG islands, making it highly susceptible to hypermethylation. During carcinogenesis, as cells dedifferentiate, the ESR2 promoter often becomes methylated, leading to gene silencing regardless of the available estrogen concentration.[17]

This finding has significant clinical relevance regarding tumor progression. The classic Yin-Yang hypothesis suggests that the loss of ERβ is a key step in the transition from a hormone-sensitive, indolent tumor to a hormone-resistant, aggressive one.[18] However, our data presents a more nuanced picture. Interestingly, our Luminal B cohort—which is clinically more aggressive and proliferative—did not show a significant drop in ERβ levels compared to Luminal A (80.83 versus 81.84). This challenges the simplistic view that aggressiveness is solely driven by the loss of the ERβ brake.

Instead, the aggressive nature of the Luminal B phenotype in our cohort appears to be driven by

the uncoupling of the E2-ERα axis rather than the loss of ERβ. In Luminal B tumors, we observed significantly lower levels of intratumoral estradiol and ERα, yet the tumors were clinically more advanced (higher Ki-67 implied by subtype). This suggests that Luminal B tumors may have evolved to bypass the estrogenic requirement entirely. Rather than relying on the E2-ERα loop for growth, these tumors likely activate alternative, ligand-independent pathways, such as the HER2, PI3K/Akt/mTOR, or MAPK signaling cascades. In this context, the presence of ERβ becomes irrelevant because the tumor is no longer driven by the ERα pathway that ERβ is meant to inhibit. This supports the clinical observation that Luminal B tumors are often resistant to endocrine monotherapy and require the addition of chemotherapy or targeted agents (like CDK4/6 inhibitors) to achieve disease control.[19]

A unique strength and differentiator of this study is the demographic profile of the cohort, which heavily favors locally advanced and metastatic disease (85.7% Stage III and IV). In contrast, the majority of large genomic datasets, such as The Cancer Genome Atlas (TCGA) or various Western consortia, are predominantly composed of early-stage, screen-detected cancers. Consequently, our findings provide a rare glimpse into the hormonal biology of survivor tumors—cancers that have grown to a substantial burden often without therapeutic intervention.

The persistence of the significant E2-ERα correlation in this advanced-stage cohort challenges the common clinical assumption that bulky, late-stage tumors become dedifferentiated and independent of hormonal signaling. Our data suggests that intracrine addiction is not merely a feature of early carcinogenesis but remains a central survival strategy even for large, advanced Luminal A tumors.[20] The metabolic demand of a large tumor mass is immense. To sustain such biomass in a postmenopausal host with negligible serum estrogen, the tumor must ramp up its local steroidogenic capacity. This has immediate implications for the management of locally advanced breast cancer (LABC) in developing regions. The data implies that neoadjuvant endocrine therapy (NET) could be a highly effective, yet underutilized, strategy for downstaging these tumors. If the tumor is maintained by a local E2-ERα loop, then high-potency Aromatase Inhibitors could induce significant tumor regression by starving the cancer of its obligate ligand. Furthermore, the variability we observed in the Luminal B group suggests that intracrine status could be a valuable biomarker. Advanced tumors that maintain high E2/ERα correlation (functioning like Luminal A) might still respond well to hormonal manipulation, whereas those with decoupled expression (functioning like Luminal B) should be triaged immediately to chemotherapy.

The divergence between systemic physiology and tumor biology underscored by this study highlights a critical limitation in current oncological practice: the reliance on serum markers to guide treatment decisions. In clinical settings, a postmenopausal woman is functionally defined by low serum estradiol. However, our study confirms that this systemic depletion is illusory at the tissue level. The high H-scores for estradiol observed in the tumor tissue confirm that the microenvironment is an active site of steroidogenesis, capable of generating concentrations 10 to 50 times higher than those found in circulation. This invisible estrogen source is likely fueled by the dual action of intratumoral aromatase and peripheral aromatization. It is crucial to consider that the majority of our patient population, consistent with global trends in breast cancer, may present with comorbidities such as obesity. Adipose tissue is the primary site of extragonadal aromatase expression. In postmenopausal women, adrenal androgens are converted to estrogens in fat depots, which then act as a reservoir of precursors (such as estrone sulfate) that the tumor can actively uptake and convert to potent estradiol via steroid sulfatase (STS).[17,18]

Consequently, a patient may be systemically estrogen-depleted but harboring a tumor that is estrogen-rich. This reinforces the absolute necessity of incorporating Aromatase Inhibitors (AIs) into the adjuvant and neoadjuvant regimens for

postmenopausal women with Luminal subtypes. While Selective Estrogen Receptor Modulators (SERMs) like Tamoxifen function by competing with estrogen for the receptor, they do not reduce the local concentration of the ligand. In a tumor with exceptionally high intracrine estradiol production (as seen in our Luminal A cohort), the sheer abundance of natural ligand might outcompete the drug, leading to therapeutic resistance. AIs, by blocking the production of the ligand itself, circumvent this competitive inhibition mechanism. Furthermore, the study points toward the potential utility of the Intratumoral E2/ERα Ratio as a novel predictive biomarker. Currently, ER status is treated as a binary or semi-quantitative variable. However, measuring the ratio of ligand to receptor could provide a functional readout of the pathway's activity. A high ratio would indicate a patent, active autocrine loop susceptible to AIs, whereas a low or disjointed ratio might indicate a tumor that has transitioned to alternative growth signaling, prompting the use of chemotherapy or targeted biological agents.

While this study utilizes robust H-Score quantification and Generalized Linear Models to account for non-normal distributions, several limitations must be acknowledged to contextualize the findings. First, the sample size of 56 patients, while sufficient for the primary correlation analysis, limits the statistical power for extensive subgroup stratification, particularly when analyzing the interaction between Stage and Receptor status. A larger, multi-center cohort would be necessary to validate these findings across diverse genetic backgrounds. Secondly, our assessment of Estrogen Receptor Beta (ERβ) utilized an antibody targeting the total ERβ protein. However, ERβ exists in multiple isoforms (such as ERβ1, ERβ2, and ERβ5), which have distinct and sometimes opposing functional roles. ERβ1 is generally considered the functional tumor suppressor, while other splice variants may have different prognostic implications.[19,20] Future studies utilizing isoform-specific antibodies could provide a higher-resolution map of the Yin-Yang balance within the tumor. Finally, the study design is cross-sectional and retrospective. While the feed-forward stabilization loop is a biologically plausible mechanism supported by extensive in vitro literature, our data demonstrates association rather than direct causation. Longitudinal studies, ideally involving paired biopsy samples taken before and after short-term presurgical aromatase inhibitor treatment (Window of Opportunity trials), would be the gold standard to definitively prove that reducing local estradiol levels leads to a concomitant downregulation of ERα protein in vivo. Additionally, incorporating quantitative RT-PCR to measure *CYP19A1* (aromatase) and *STS* (sulfatase) mRNA levels would provide a direct molecular link between the enzymatic machinery and the protein levels observed.

5. Conclusion

This study provides compelling evidence that intratumoral estradiol is a critical, independent determinant of ERα expression in luminal breast cancer, establishing a positive correlation that fuels tumor maintenance and proliferation through a local autocrine loop. This relationship is not merely an artifact of early disease but persists as a dominant driver even in locally advanced and metastatic tumors, challenging the assumption that late-stage cancers are invariably hormone-independent. The distinct regulation of the two receptor isoforms is evident: while ERα levels are tightly coupled to local ligand availability (particularly in the Luminal A subtype), ERβ expression appears independent of estradiol concentrations, reinforcing its role as a distinct, likely epigenetically regulated, tumor suppressor.

The dominance of the E2-ERα axis in our cohort validates the biological rationale for therapies that specifically deplete local estrogen synthesis. The data suggest that for postmenopausal women with Luminal A breast cancer, the tumor microenvironment functions as a sanctuary of estrogen production, necessitating the use of Aromatase Inhibitors to dismantle the intracrine loop. Conversely, the decoupling of this axis in Luminal B tumors points to

the activation of alternative survival pathways, requiring more aggressive multimodal treatment strategies. Moving forward, the field of breast oncology must evolve beyond the binary assessment of serum hormones and receptor status. Integrating the concept of intracrineology into clinical decision-making—potentially through the development of biomarkers that quantify the local ligand-receptor ratio—offers a promising avenue for refining prognosis and personalizing therapeutic regimens. By targeting not just the receptor, but the local fuel supply that sustains it, we can optimize outcomes for the significant population of women presenting with advanced, hormone-dependent malignancies.

6. References

1. Arnesen S, Polaski JT, Blanchard Z, Osborne KS, Welm AL, O'Connell RM, et al. Estrogen receptor alpha mutations regulate gene expression and cell growth in breast cancer through microRNAs. NAR Cancer. 2023; 5(2): zcad027.
2. Danielsson O, Dar H, Perez-Tenorio G, Nordenskjöld A, Yau C, Benz CC, et al. Progesterone receptor (PR) intra-tumor heterogeneity in premenopausal breast cancer: a secondary analysis of a randomized trial. Int J Cancer. 2026; 158(4): 1106–15.
3. Kaukonen D, Ploner A, Zeng E, Bergqvist J, Czene K. Evaluating distant recurrence-free survival and location of metastasis in HER2+ breast cancer by ER status. Int J Cancer. 2026; 158(5): 1184–92.
4. Fu M, Peng Z, Wu M, Lv D, Li Y, Lyu S. Current and future burden of breast cancer in Asia: a GLOBOCAN data analysis for 2022 and 2050. Breast. 2025; 79(103835): 103835.
5. Zhang Y, Ji Y, Liu S, Li J, Wu J, Jin Q, et al. Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN. J Natl Cancer Cent. 2025; 5(3): 287–96.
6. Zahwe M, Bendahhou K, Eser S, Mukherji D, Fouad H, Fadhil I, et al. Current and future burden of female breast cancer in the Middle East and North Africa region using estimates from GLOBOCAN 2022. Int J Cancer. 2025; 156(12): 2320–9.
7. Wang X, Emch MJ, Goetz MP, Hawse JR. Anti-neoplastic activity of estrogen receptor beta in chemoresistant triple-negative breast cancer. Cancers (Basel). 2025; 17(13): 2132.
8. Biganzoli G, Isnaldi E, Richard F, Marano G, Boracchi P, Maetens M, et al. Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: a retrospective analysis of the SOLE trial. Eur J Cancer. 2025; 222(115438): 115438.
9. Morganti S, Chu X, Ballinger TJ, Unni N, Sinclair S, Wesolowski R, et al. A randomized phase 2 study of neratinib with or without fulvestrant for patients with HER2-positive, estrogen receptor-positive metastatic breast cancer. Clin Breast Cancer. 2025; 25(6): 566-574.e2.
10. Yan P, Wu F, Afanasyeva Y, Arslan A, Koenig K, Zeleniuch-Jacquotte A, et al. Premenopausal serum midkine levels and risk of estrogen receptor positive breast cancer: a prospective, nested case-control study. Breast Cancer Res. 2026.
11. Liu S, Du B, Zhang M, Zhai D, Zhao X, Shao N, et al. Prognosis and endocrine therapy efficacy in early breast cancer with estrogen receptor low expression. Breast Cancer Res Treat. 2026; 215(2): 51.
12. Yılmaz M, Erdiş E, Uçar M, Yücel B. Prognostic importance of panimmune-inflammation value and PILE scores in non-metastatic luminal A breast cancer. Breast Care (Basel). 2025; 20(1): 27–39.
13. Di Leone A, Franco A, Castagnetta V, Silenzi M, Accetta C, Carnassale B, et al.

Personalizing neoadjuvant chemotherapy: The impact of BRCA variants on pathologic complete response in luminal B breast cancer. Cancers (Basel). 2025; 17(10): 1619.

14. De Placido P, Di Rienzo R, Pietroluongo E, Martinelli C, Tafuro M, Formisano P, et al. Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study. Eur J Cancer. 2025; 221(115409): 115409.
15. Cazzaniga ME, Pronzato P, Amoroso D, Arpino G, Atzori F, Beano A, et al. Survival outcomes of Luminal metastatic breast cancer patients according to changes in molecular subtype at re-biopsy: Insights from the GIM-13-AMBRA study. Cancers (Basel). 2025; 17(10): 1715.
16. Gemci ÖD, Altınay S, Gültürk İ, Tural D, Karabulut M, Sakız DN. Prognostic importance of PTEN and P53 in aggressive luminal A subtype breast cancers. Eur J Breast Health. 2025; 21(3): 246–54.
17. Garufi G, Mastrantoni L, Maliziola N, Di Monte E, Arcuri G, Frescura V, et al. Activity and efficacy of neoadjuvant chemotherapy in luminal-HER2 negative early breast cancer according to HER2 score (low vs. Score 0): a retrospective study. Clin Breast Cancer. 2025; 25(5): 431-443.e5.
18. Fischer U. Tumor growth rate of luminal and nonluminal invasive breast cancer calculated on MRI imaging. Clin Breast Cancer. 2025; 25(5): 422–30.
19. Zhu M, Lin J, Liu H, Wang J, Liu N, Li Y, et al. Construction and validation of acetylation-related gene signatures for immune landscape analysis and prognostication risk prediction in luminal breast cancer. Cancer Cell Int. 2025; 25(1): 287.
20. Nur MMH, Prihantono P, Kusuma MI, Indra I, Syamsu SA, Smaradhania N, et al. MTOR levels and metastasis in luminal breast cancer: Implications for prognosis and treatment. Asian Pac J Cancer Prev. 2025; 26(9): 3347–52.